Login to Your Account

Other News To Note

Wednesday, March 7, 2012

• BioLineRx Ltd., of Jerusalem, closed its $15 million private placement with U.S. institutional investors. The company sold about 5.25 million American Depositary Shares (ADSs) at $2.86 per ADS and warrants to purchase up to 2.6 million additional ADSs at an exercise price of $3.57 each, netting BioLineRx around $14.1 million. Roth Capital Management LLC acted as sole placement agent. In other news, BioLineRx received approval from the Israeli Ministry of Health to begin a Phase II trial of BL-7040 for inflammatory bowel disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription